following a full submission:
obinutuzumab (Gazyvaro) is accepted for use within NHSScotland.
Indication under review: In combination with chlorambucil, obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy.
The combination of obinutuzumab plus chlorambucil produced a statistically and clinically significant increase in progression free survival compared with an alkylating agent alone or an alkylating agent/antibody combination, in older patients with previously untreated CLL who had substantial comorbidities.
Download detailed advice270KB (PDF)
Medicine details
- Medicine name:
- obinutuzumab (Gazyvaro)
- SMC ID:
- 1008/14
- Indication:
In combination with chlorambucil, obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy.
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 December 2014